EN
Merck and Moderna's melanoma vaccine becomes first mRNA cancer therapy approved in Phase 3 trial
Merck and Moderna's mRNA melanoma vaccine demonstrated significant improvements in Phase 3 trials when combined with Keytruda, marking the first successful